-
Something wrong with this record ?
Urine markers in monitoring for prostate cancer
T. Jamaspishvili, M. Kral, I. Khomeriki, V. Student, Z. Kolar, J. Bouchal
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NS9940
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
ProQuest Central
from 2000-07-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 1997-09-01 to 2015-12-31
Health & Medicine (ProQuest)
from 2000-07-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-07-01 to 1 year ago
PubMed
19652665
DOI
10.1038/pcan.2009.31
Knihovny.cz E-resources
- MeSH
- Annexin A3 urine MeSH
- Antigens, Neoplasm urine MeSH
- Gene Fusion MeSH
- Oncogene Proteins, Fusion urine MeSH
- Glutathione S-Transferase pi urine MeSH
- Humans MeSH
- Matrix Metalloproteinase 9 urine MeSH
- Biomarkers, Tumor urine MeSH
- Prostatic Neoplasms genetics urine MeSH
- Prognosis MeSH
- Prostate-Specific Antigen urine MeSH
- Racemases and Epimerases urine MeSH
- Sarcosine urine MeSH
- Comparative Genomic Hybridization MeSH
- Telomerase urine MeSH
- Vascular Endothelial Growth Factor A urine MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
The major advantages of urine-based assays are their noninvasive character and ability to monitor prostate cancer with heterogeneous foci. Almost all urine-detectable prostate-specific markers have been recently reviewed. For this reason, we focus here on only a few promising markers which have been independently evaluated (in particular PCA3, fusion genes, TERT, AMACR, GSTP1, MMP9 and VEGF) and very recent ones (ANXA3 and sarcosine). The emphasis is also on multiplex biomarker analysis and on microarray-based analysis of fusion genes. A combination of multiple urine biomarkers may be valuable in the case of men with persistently elevated serum prostate-specific antigen and a history of negative biopsies. The emerging urine tests should help in both early diagnosis of prostate cancer and identifying aggressive tumors for radical treatment.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025554
- 003
- CZ-PrNML
- 005
- 20141113093937.0
- 007
- ta
- 008
- 120816s2010 enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1038/pcan.2009.31 $2 doi
- 035 __
- $a (PubMed)19652665
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Jamaspishvili, T. $7 xx0281436 $u Laboratory of Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 245 10
- $a Urine markers in monitoring for prostate cancer / $c T. Jamaspishvili, M. Kral, I. Khomeriki, V. Student, Z. Kolar, J. Bouchal
- 520 9_
- $a The major advantages of urine-based assays are their noninvasive character and ability to monitor prostate cancer with heterogeneous foci. Almost all urine-detectable prostate-specific markers have been recently reviewed. For this reason, we focus here on only a few promising markers which have been independently evaluated (in particular PCA3, fusion genes, TERT, AMACR, GSTP1, MMP9 and VEGF) and very recent ones (ANXA3 and sarcosine). The emphasis is also on multiplex biomarker analysis and on microarray-based analysis of fusion genes. A combination of multiple urine biomarkers may be valuable in the case of men with persistently elevated serum prostate-specific antigen and a history of negative biopsies. The emerging urine tests should help in both early diagnosis of prostate cancer and identifying aggressive tumors for radical treatment.
- 650 _2
- $a annexin A3 $x moč $7 D017318
- 650 _2
- $a antigeny nádorové $x moč $7 D000951
- 650 _2
- $a srovnávací genomová hybridizace $7 D055028
- 650 _2
- $a fúze genů $7 D050939
- 650 _2
- $a glutathion-S-transferasa fí $x moč $7 D051549
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a matrixová metaloproteinasa 9 $x moč $7 D020780
- 650 _2
- $a fúzní onkogenní proteiny $x moč $7 D015514
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prostatický specifický antigen $x moč $7 D017430
- 650 _2
- $a nádory prostaty $x genetika $x moč $7 D011471
- 650 _2
- $a racemasy a epimerasy $x moč $7 D019998
- 650 _2
- $a sarkosin $x moč $7 D012521
- 650 _2
- $a telomerasa $x moč $7 D019098
- 650 _2
- $a nádorové biomarkery $x moč $7 D014408
- 650 _2
- $a vaskulární endoteliální růstový faktor A $x moč $7 D042461
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Král, Milan $7 xx0079094
- 700 1#
- $a Khomeriki, Irakli. $7 _AN065375
- 700 1_
- $a Študent, Vladimír, $d 1958- $7 ola2003199603
- 700 1_
- $a Kolář, Zdeněk, $d 1953- $7 jn20000710256
- 700 1_
- $a Bouchal, Jan, $d 1973- $7 xx0034399
- 773 0_
- $w MED00008064 $t Prostate cancer and prostatic diseases $x 1476-5608 $g Roč. 13, č. 1 (2010), s. 12-19
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/19652665 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20141113093951 $b ABA008
- 999 __
- $a ok $b bmc $g 947596 $s 782900
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 13 $c 1 $d 12-19 $i 1476-5608 $m Prostate cancer and prostatic diseases $n Prostate Cancer Prostatic Dis $x MED00008064
- GRA __
- $a NS9940 $p MZ0
- LZP __
- $a Pubmed-20120816/10/02
